Non-alcoholic fatty liver disease (NAFLD) models in drug discovery

References

• Loomba R, Sanyal AJ. The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol. 2013;10:686–690.
   PubMed Web of Science ®Google Scholar
• Falck-Ytter Y, Younossi ZM, Marchesini G, et al. Clinical features and natural history of nonalcoholic steatosis syndromes. Semin Liver Dis. 2001;21:17–26.
   PubMed Web of Science ®Google Scholar
• Medina J, Fernandez-Salazar LI, Garcia-Buey L, et al. Approach to the pathogenesis and treatment of nonalcoholic steatohepatitis. Diabetes Care. 2004;27:2057–2066.
   PubMed Web of Science ®Google Scholar
• Dongiovanni P, Anstee QM, Valenti L. Genetic predisposition in NAFLD and NASH: impact on severity of liver disease and response to treatment. Curr Pharm Des. 2013;19:5219–5238.
   PubMed Web of Science ®Google Scholar
• Cusi K, Sanyal AJ, Zhang S, et al. Non-alcoholic fatty liver disease (NAFLD) prevalence and its metabolic associations in patients with type 1 diabetes and type 2 diabetes. Diabetes Obes Metab. 2017;19:1630–1634.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov.[Internet].  Bethesda, MD: US National Library of Medicine; cited 2017. Available from: ClinicalTrials.gov
   Google Scholar
• 2017. Available from: nashbiotechs.com[Internet]. cited 2017. Available from: nashbiotechs.com
   Google Scholar
• Banini BA, Sanyal AJ. Current and future pharmacologic treatment of nonalcoholic steatohepatitis. Curr Opin Gastroenterol. 2017;33:134–141.
   PubMed Web of Science ®Google Scholar
• Galectin Therapeutics. Galectin therapeutics announces top-line data from exploratory phase 2a pilot trial (NASH-FX) with GR-MD-02 in NASH patients with advanced fibrosis. Galetin Therapeutics [Internet]. 2016 Sept 27; Press release:[about 4 screens]. Available from: http://investor.galectintherapeutics.com/news-releases/news-release-details/galectin-therapeutics-announces-top-line-data-exploratory-phase
   Google Scholar
• Gilead. Gilead announces top-line phase 2 results for GS-4997 (Selonsertib) in nonalcoholic steatohepatitis (NASH), pulmonary arterial hypertension (PAH) and diabetic kidney disease (DKD). Gilead [Internet]. 2016 Oct 20; Press release:[about 3 screens]. Available from: http://www.gilead.com/news/press-releases/2016/10/gilead-announces-topline-phase-2-results-for-gs4997-selonsertib-in-nonalcoholic-steatohepatitis-nash-pulmonary-arterial-hypertension-pah-and-diabetic-kidney-disease-dkd
   Google Scholar
• Raptor Pharmaceuticals. Raptor pharmaceutical provides topline results From phase 2b CyNCh study evaluating RP103 in pediatric nonalcoholic steatohepatitis. Nasdaq Globe Newswire [Internet]. 2015 Sept 14; Press release:[about 4 screens]. Available from: https://globenewswire.com/news-release/2015/09/14/767963/10149175/en/Raptor-Pharmaceutical-Provides-Topline-Results-From-Phase-2b-CyNCh-Study-Evaluating-RP103-in-Pediatric-Nonalcoholic-Steatohepatitis.html
   Google Scholar
• Jacobs A, Warda AS, Verbeek J, et al. An overview of mouse models of nonalcoholic steatohepatitis: from past to present. Curr Protoc Mouse Biol. 2016;6:185–200.
   PubMedGoogle Scholar
• Kanuri G, Bergheim I. In vitro and in vivo models of non-alcoholic fatty liver disease (NAFLD). Int J Mol Sci. 2013;14:11963–11980.
   PubMed Web of Science ®Google Scholar
• Sanches SC, Ramalho LN, Augusto MJ, et al. Nonalcoholic steatohepatitis: a search for factual animal models. Biomed Res Int. 2015;2015:574832.
   PubMed Web of Science ®Google Scholar
• Teufel A, Itzel T, Erhart W, et al. Comparison of gene expression patterns between mouse models of nonalcoholic fatty liver disease and liver tissues from patients. Gastroenterology. 2016;151:513–525 e510.
   PubMed Web of Science ®Google Scholar
• Karnik S, Charlton M, Li L, et al. Efficacy of an ASK1 inhibitor to reduce fibrosis and steatosis in a murine model of NASH is associated with normalization of lipids and hepatic gene expression and a reduction in serum biomarkers of inflammation and fibrosis. Poster session presented at: AALSD Liver Meeting; 2015 Nov 13-17; San Francisco, CA.
   Google Scholar
• Ling L. Human FGF19 but not NGM282, an engineered variant of FGF19, causes hepatocellular carcinoma (HCC) in a diet-induced mouse model of non-alcoholic steatohepatitis (NASH). Poster session presented at: AALSD Liver Meeting; 2016 Nov 11-15; Boston, MA.
   Google Scholar
• Barreyro FJ, Holod S, Finocchietto PV, et al. The pan-caspase inhibitor Emricasan (IDN-6556) decreases liver injury and fibrosis in a murine model of non-alcoholic steatohepatitis. Liver Int. 2015;35:953–966.
   PubMed Web of Science ®Google Scholar
• Tolbol KV, S.S., Kristiansen, M.; Vrang, N. Jelsing, J.; Feigh, M. The GLP-1 analogue, liraglutide, reduces NAFLD Activity Score and Fibrosis Stage and improves metabolic parameters in a diet-induced obese mouse model of biopsy-confirmed non-alcoholic steatohepatitis (NASH). Poster session presented at: AALSD Liver Meeting; 2016 Nov 11-15; Boston, MA.
   Google Scholar
• Sanyal Biotechnology. Immuron initiates NASH MOA studies with sanyalbio and with Duke University. Sanyal Biotechnology [Internet]. 2017 Jan 19; Press release:[about 3 screens]. Available from: https://www.sanyalbio.com/immuron-initiates-nash-moa-studies-sanyalbio-duke-university/
   Google Scholar
• Staels B, Rubenstrunk A, Noel B, et al. Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Hepatology. 2013;58:1941–1952.
   PubMed Web of Science ®Google Scholar
• Roth J, Feigh M, Veidal S, et al., et al. Obeticholic acid improves histological, biochemical and gene expression profiles in Gubra AMLN mice with biopsy-confirmed NASH. In: The International Liver 840 Congress Meeting, EASL. Amsterdam, The Netherlands; 2017.
   Google Scholar
• Hum D, Sanyal A, Harrison S, et al. Elafibranor: a liver targeted PPARα/δ agonist for a global management of nash patients. Poster session presented at: The International Liver Congress Meeting, EASL; 2016 April 13-17; Barcelona, Spain.
   Google Scholar
• Traber PG, Zomer E. Therapy of experimental NASH and fibrosis with galectin inhibitors. PLoS One. 2013;8:e83481.
   PubMed Web of Science ®Google Scholar
• Lefebvre E, Moyle G, Reshef R, et al. Antifibrotic effects of the dual CCR2/CCR5 antagonist cenicriviroc in animal models of liver and kidney fibrosis. PLoS One. 2016;11:e0158156.
   PubMed Web of Science ®Google Scholar
• Krupinski J. Effects of BMS-986036 (pegylated fibroblast growth factor 21) on hepatic steatosis and fibrosis in a mouse model of nonalcoholic steatohepatitis. Poster session presented at: AALSD Liver Meeting; 2016 Nov 11-15; Boston, MA.
   Google Scholar
• Tetri LH, Basaranoglu M, Brunt EM, et al. Severe NAFLD with hepatic necroinflammatory changes in mice fed trans fats and a high-fructose corn syrup equivalent. Am J Physiol Gastrointest Liver Physiol. 2008;295:G987–G995.
   PubMed Web of Science ®Google Scholar
• Dowman JK, Hopkins LJ, Reynolds GM, et al. Development of hepatocellular carcinoma in a murine model of nonalcoholic steatohepatitis induced by use of a high-fat/fructose diet and sedentary lifestyle. Am J Pathol. 2014;184:1550–1561.
   PubMed Web of Science ®Google Scholar
• Asgharpour A, Cazanave SC, Pacana T, et al. A diet-induced animal model of non-alcoholic fatty liver disease and hepatocellular cancer. J Hepatol. 2016;65:579–588.
   PubMed Web of Science ®Google Scholar
• Rinella ME, Green RM. The methionine-choline deficient dietary model of steatohepatitis does not exhibit insulin resistance. J Hepatol. 2004;40:47–51.
   PubMed Web of Science ®Google Scholar
• Wang B, Chandrasekera PC, Pippin JJ. Leptin- and leptin receptor-deficient rodent models: relevance for human type 2 diabetes. Curr Diabetes Rev. 2014;10:131–145.
   PubMedGoogle Scholar
• Kelesidis T, Kelesidis I, Chou S, et al. Narrative review: the role of leptin in human physiology: emerging clinical applications. Ann Intern Med. 2010;152:93–100.
   PubMed Web of Science ®Google Scholar
• Collin GB, Cyr E, Bronson R, et al. Alms1-disrupted mice recapitulate human Alstrom syndrome. Hum Mol Genet. 2005;14:2323–2333.
   PubMed Web of Science ®Google Scholar
• Sahai A, Malladi P, Pan X, et al. Obese and diabetic db/db mice develop marked liver fibrosis in a model of nonalcoholic steatohepatitis: role of short-form leptin receptors and osteopontin. Am J Physiol Gastrointest Liver Physiol. 2004;287:G1035–G1043.
   PubMed Web of Science ®Google Scholar
• Liedtke C, Luedde T, Sauerbruch T, et al. Experimental liver fibrosis research: update on animal models, legal issues and translational aspects. Fibrogenesis Tissue Repair. 2013;6:19.
   PubMedGoogle Scholar
• Fujii M, Shibazaki Y, Wakamatsu K, et al. A murine model for non-alcoholic steatohepatitis showing evidence of association between diabetes and hepatocellular carcinoma. Med Mol Morphol. 2013;46:141–152.
   PubMed Web of Science ®Google Scholar
• Barter PJ, Brewer HB Jr., Chapman MJ, et al. Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis. Arterioscler Thromb Vasc Biol. 2003;23:160–167.
   PubMed Web of Science ®Google Scholar
• Kowalski GM, Bruce CR. The regulation of glucose metabolism: implications and considerations for the assessment of glucose homeostasis in rodents. Am J Physiol Endocrinol Metab. 2014;307:E859–E871.
   PubMed Web of Science ®Google Scholar
• Martignoni M, Groothuis GM, de Kanter R. Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction. Expert Opin Drug Metab Toxicol. 2006;2:875–894.
   PubMed Web of Science ®Google Scholar
• Walsh NC, Kenney LL, Jangalwe S, et al. Humanized mouse models of clinical disease. Annu Rev Pathol. 2017;12:187–215.
   PubMed Web of Science ®Google Scholar
• Baker TK, Carfagna MA, Gao H, et al. Temporal gene expression analysis of monolayer cultured rat hepatocytes. Chem Res Toxicol. 2001;14:1218–1231.
   PubMed Web of Science ®Google Scholar
• Boess F, Kamber M, Romer S, et al. Gene expression in two hepatic cell lines, cultured primary hepatocytes, and liver slices compared to the in vivo liver gene expression in rats: possible implications for toxicogenomics use of in vitro systems. Toxicol Sci. 2003;73:386–402.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Antona C, Donato MT, Boobis A, et al. Cytochrome P450 expression in human hepatocytes and hepatoma cell lines: molecular mechanisms that determine lower expression in cultured cells. Xenobiotica. 2002;32:505–520.
   PubMed Web of Science ®Google Scholar
• Wilkening S, Stahl F, Bader A. Comparison of primary human hepatocytes and hepatoma cell line Hepg2 with regard to their biotransformation properties. Drug Metab Dispos. 2003;31:1035–1042.
   PubMed Web of Science ®Google Scholar
• Nelson LJ, Treskes P, Howie AF, et al. Profiling the impact of medium formulation on morphology and functionality of primary hepatocytes in vitro. Sci Rep. 2013;3:2735.
   PubMed Web of Science ®Google Scholar
• Suckale J, Solimena M. Pancreas islets in metabolic signaling–focus on the beta-cell. Front Biosci. 2008;13:7156–7171.
   PubMed Web of Science ®Google Scholar
• Bertrand F, Philippe C, Antoine PJ, et al. Insulin activates nuclear factor kappa B in mammalian cells through a Raf-1-mediated pathway. J Biol Chem. 1995;270:24435–24441.
   PubMed Web of Science ®Google Scholar
• Cai D, Yuan M, Frantz DF, et al. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat Med. 2005;11:183–190.
   PubMed Web of Science ®Google Scholar
• Ke B, Zhao Z, Ye X, et al. Inactivation of NF-kappaB p65 (RelA) in liver improves insulin sensitivity and inhibits cAMP/PKA pathway. Diabetes. 2015;64:3355–3362.
   PubMed Web of Science ®Google Scholar
• Graaf IA, Groothuis GM, Olinga P. Precision-cut tissue slices as a tool to predict metabolism of novel drugs. Expert Opin Drug Metab Toxicol. 2007;3:879–898.
   PubMed Web of Science ®Google Scholar
• Olinga P, Schuppan D. Precision-cut liver slices: a tool to model the liver ex vivo. J Hepatol. 2013;58:1252–1253.
   PubMed Web of Science ®Google Scholar
• Neupert D, Glockner R, Neupert G, et al. Ultrastructural changes in hepatocytes of precision-cut rat liver slices after incubation for 24 and 48 hours. Exp Toxicol Pathol. 2003;54:481–488.
   PubMed Web of Science ®Google Scholar
• de Kanter R, Monshouwer M, Meijer DK, et al. Precision-cut organ slices as a tool to study toxicity and metabolism of xenobiotics with special reference to non-hepatic tissues. Curr Drug Metab. 2002;3:39–59.
   PubMed Web of Science ®Google Scholar
• Soldatow VY, Lecluyse EL, Griffith LG, et al. In vitro models for liver toxicity testing. Toxicol Res (Camb). 2013;2:23–39.
   PubMed Web of Science ®Google Scholar
• Dash A, Blackman BR, Wamhoff BR. Organotypic systems in drug metabolism and toxicity: challenges and opportunities. Expert Opin Drug Metab Toxicol. 2012;8:999–1014.
   PubMed Web of Science ®Google Scholar
• Dash A, Inman W, Hoffmaster K, et al. Liver tissue engineering in the evaluation of drug safety. Expert Opin Drug Metab Toxicol. 2009;5:1159–1174.
   PubMed Web of Science ®Google Scholar
• LeCluyse EL, Witek RP, Andersen ME, et al. Organotypic liver culture models: meeting current challenges in toxicity testing. Crit Rev Toxicol. 2012;42:501–548.
   PubMed Web of Science ®Google Scholar
• Ijssennagger N, Janssen AW, Milona A, et al. Gene expression profiling in human precision cut liver slices in response to the FXR agonist obeticholic acid. J Hepatol. 2016;64:1158–1166.
   PubMed Web of Science ®Google Scholar
• Janssen AW, Betzel B, Stoopen G, et al. The impact of PPARalpha activation on whole genome gene expression in human precision cut liver slices. BMC Genomics. 2015;16:760.
   PubMed Web of Science ®Google Scholar
• Davidson MD, Ballinger KR, Khetani SR. Long-term exposure to abnormal glucose levels alters drug metabolism pathways and insulin sensitivity in primary human hepatocytes. Sci Rep. 2016;6:28178.
   PubMed Web of Science ®Google Scholar
• Davidson MD, Kukla DA, Khetani SR. Microengineered cultures containing human hepatic stellate cells and hepatocytes for drug development. Integr Biol (Camb). 2017;9:662–677.
   PubMed Web of Science ®Google Scholar
• Kostrzewski T, Cornforth T, Snow SA, et al. Three-dimensional perfused human in vitro model of non-alcoholic fatty liver disease. World J Gastroenterol. 2017;23:204–215.
   PubMed Web of Science ®Google Scholar
• Feaver RE, Cole BK, Lawson MJ, et al. Development of an in vitro human liver system for interrogating nonalcoholic steatohepatitis. JCI Insight. 2016;1:e90954.
   PubMed Web of Science ®Google Scholar
• Dash A, Figler RA, Sanyal AJ, et al. Drug-induced steatohepatitis. Expert Opinion on Drug Metabolism & Toxicology 2016; 13:193-204.
   Google Scholar
• Feaver R, Cole B, Hoang S, et al. Identification of novel targets for nonalcoholic steatohepatitis using a human surrogate system. Poster session presented at: AASLD Liver Meeting; 2017 Oct 20-24; Washington, D.C.
   Google Scholar
• Guillouzo A, Corlu A, Aninat C, et al. The human hepatoma HepaRG cells: a highly differentiated model for studies of liver metabolism and toxicity of xenobiotics. Chem Biol Interact. 2007;168:66–73.
   PubMed Web of Science ®Google Scholar
• Hart SN, Li Y, Nakamoto K, et al. A comparison of whole genome gene expression profiles of HepaRG cells and HepG2 cells to primary human hepatocytes and human liver tissues. Drug Metab Dispos. 2010;38:988–994.
   PubMed Web of Science ®Google Scholar
• Riccalton-Banks L, Liew C, Bhandari R, et al. Long-term culture of functional liver tissue: three-dimensional coculture of primary hepatocytes and stellate cells. Tissue Eng. 2003;9:401–410.
   PubMedGoogle Scholar
• Fausto N, Campbell JS, Riehle KJ. Liver regeneration. J Hepatol. 2012;57:692–694.
   PubMed Web of Science ®Google Scholar
• Krause P, Saghatolislam F, Koenig S, et al. Maintaining hepatocyte differentiation in vitro through co-culture with hepatic stellate cells. In Vitro Cell Dev Biol Anim. 2009;45:205–212.
   PubMed Web of Science ®Google Scholar
• Boulton R, Woodman A, Calnan D, et al. Nonparenchymal cells from regenerating rat liver generate interleukin-1alpha and −1beta: a mechanism of negative regulation of hepatocyte proliferation. Hepatology. 1997;26:49–58.
   PubMed Web of Science ®Google Scholar
• Schirmacher P, Geerts A, Pietrangelo A, et al. Hepatocyte growth factor/hepatopoietin A is expressed in fat-storing cells from rat liver but not myofibroblast-like cells derived from fat-storing cells. Hepatology. 1992;15:5–11.
   PubMed Web of Science ®Google Scholar
• Mullhaupt B, Feren A, Fodor E, et al. Liver expression of epidermal growth factor RNA. Rapid increases in immediate-early phase of liver regeneration. J Biol Chem. 1994;269:19667–19670.
   PubMed Web of Science ®Google Scholar
• Wake K. Cell-cell organization and functions of ‘sinusoids’ in liver microcirculation system. J Electron Microsc (Tokyo). 1999;48:89–98.
   PubMedGoogle Scholar
• Weiskirchen R, Tacke F. Cellular and molecular functions of hepatic stellate cells in inflammatory responses and liver immunology. Hepatobiliary Surg Nutr. 2014;3:344–363.
   PubMedGoogle Scholar
• Friedman SL. Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiol Rev. 2008;88:125–172.
   PubMed Web of Science ®Google Scholar
• Duarte N, Coelho IC, Patarrao RS, et al. How inflammation impinges on NAFLD: a role for kupffer cells. Biomed Res Int. 2015;2015:984578.
   PubMed Web of Science ®Google Scholar
• Magee N, Zou A, Zhang Y. Pathogenesis of nonalcoholic steatohepatitis: interactions between liver parenchymal and nonparenchymal cells. Biomed Res Int. 2016;2016:5170402.
   PubMed Web of Science ®Google Scholar
• Chang SY, Weber EJ, Ness KV, et al. Liver and kidney on chips: microphysiological models to understand transporter function. Clin Pharmacol Ther. 2016;100:464–478.
   PubMed Web of Science ®Google Scholar
• Lin C, Ballinger KR, Khetani SR. The application of engineered liver tissues for novel drug discovery. Expert Opin Drug Discov. 2015;10:519–540.
   PubMed Web of Science ®Google Scholar
• Organovo. Organovo and its customers present data supporting 3D bioprinted liver tissues for drug toxicity testing and liver fibrosis modeling. Organovo [Internet]. 2016 March 10; Press release:[about 4 screens]. Available from: http://phx.corporate-ir.net/phoenix.zhtml?c=254194&p=irol-newsArticle&ID=2147586
   Google Scholar
• Organovo. Organovo and UC San Diego receive $1.7 million grant from national institutes of health to study liver disease. 2017 July 31; Press release:[about 4 screens]. Available from: http://phx.corporate-ir.net/phoenix.zhtml?c=254194&p=irol-newsArticle&ID=2290135
   Google Scholar
• Gori M, Simonelli MC, Giannitelli SM, et al. Investigating nonalcoholic fatty liver disease in a liver-on-a-chip microfluidic device. PLoS One. 2016;11:e0159729.
   PubMed Web of Science ®Google Scholar
• Lee PJ, Hung PJ, Lee LP. An artificial liver sinusoid with a microfluidic endothelial-like barrier for primary hepatocyte culture. Biotechnol Bioeng. 2007;97:1340–1346.
   PubMed Web of Science ®Google Scholar
• Domansky K, Inman W, Serdy J, et al. Perfused multiwell plate for 3D liver tissue engineering. Lab Chip. 2010;10:51–58.
   PubMed Web of Science ®Google Scholar
• Dash A, Figler RA, Blackman BR, et al. Pharmacotoxicology of clinically-relevant concentrations of obeticholic acid in an organotypic human hepatocyte system. Toxicol In Vitro. 2017;39:93–103.
   PubMed Web of Science ®Google Scholar
• Dash A, Simmers MB, Deering TG, et al. Hemodynamic flow improves rat hepatocyte morphology, function, and metabolic activity in vitro. Am J Physiol Cell Physiol. 2013;304:C1053–C1063.
   PubMed Web of Science ®Google Scholar
• Terelius Y, Figler RA, Marukian S, et al. Transcriptional profiling suggests that Nevirapine and Ritonavir cause drug induced liver injury through distinct mechanisms in primary human hepatocytes. Chem Biol Interact. 2015;255:31–44.
   PubMed Web of Science ®Google Scholar
• De Almeida IT, Cortez-Pinto H, Fidalgo G, et al. Plasma total and free fatty acids composition in human non-alcoholic steatohepatitis. Clin Nutr. 2002;21:219–223.
   PubMed Web of Science ®Google Scholar
• Puri P, Baillie RA, Wiest MM, et al. A lipidomic analysis of nonalcoholic fatty liver disease. Hepatology. 2007;46:1081–1090.
   PubMed Web of Science ®Google Scholar
• Smith U. Pioglitazone: mechanism of action. Int J Clin Pract Suppl. 2001;121:13-18.
   Google Scholar
• Hirschfield GM, Mason A, Luketic V, et al. Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid. Gastroenterology. 2015;148(751–761):e758.
   Google Scholar
• Neuschwander-Tetri BA, Loomba R, Sanyal AJ, et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet. 2015;385:956–965.
   PubMed Web of Science ®Google Scholar
• Ali AH, Carey EJ, Lindor KD. Recent advances in the development of farnesoid X receptor agonists. Ann Transl Med. 2015;3:5.
   PubMed Web of Science ®Google Scholar
• Cariou B, van Harmelen K, Duran-Sandoval D, et al. The farnesoid X receptor modulates adiposity and peripheral insulin sensitivity in mice. J Biol Chem. 2006;281:11039–11049.
   PubMed Web of Science ®Google Scholar
• Sinal CJ, Tohkin M, Miyata M, et al. Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis. Cell. 2000;102:731–744.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Lee FY, Barrera G, et al. Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. Proc Natl Acad Sci U S A. 2006;103:1006–1011.
   PubMed Web of Science ®Google Scholar
• Fisher CD, Lickteig AJ, Augustine LM, et al. Hepatic cytochrome P450 enzyme alterations in humans with progressive stages of nonalcoholic fatty liver disease. Drug Metab Dispos. 2009;37:2087–2094.
   PubMed Web of Science ®Google Scholar
• Lake AD, Novak P, Fisher CD, et al. Analysis of global and absorption, distribution, metabolism, and elimination gene expression in the progressive stages of human nonalcoholic fatty liver disease. Drug Metab Dispos. 2011;39:1954–1960.
   PubMed Web of Science ®Google Scholar
• Chtioui H, Semela D, Ledermann M, et al. Expression and activity of the cytochrome P450 2E1 in patients with nonalcoholic steatosis and steatohepatitis. Liver Int. 2007;27:764–771.
   PubMed Web of Science ®Google Scholar